Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March and April:

A presentation at the 46 th Annual TD Cowen Health Care Conference at 11:50 a.m. ET Monday, March 2, 2026

A fireside chat at Leerink’s Global Healthcare Conference at 10:00 a.m. ET on Monday, March 9, 2026

A fireside chat at the 25 th Annual Needham Virtual Healthcare Conference at 9:30 a.m. ET on Monday, April 13, 2026

Live webcasts of the fireside chats and presentation are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com , where an archived replay of the events will also be available for a limited time.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X .

Investor Contact

Megan LeDuc Associate Director, Investor Relations [email protected]

Media Contact

David Rosen Argot Partners [email protected]